Preclinical
Adaptimmune reported it saw three partial responses in three of the four myxoid/ round cell liposarcoma (MRCLS) patients the company dosed with its NY-ESO SPEAR T-cells.
Gilead Sciences announced promising results from a preclinical trial conducted with Beth Israel Deaconess Medical Center as part of an HIV eradication strategy.
The U.S. Food and Drug Administration (FDA) issued new draft guidance for preclinical trials in Alzheimer’s.
PRESS RELEASES